Braftide – Cancer Peptides

BRAF dimers are a core component of the MAPK cascade to pass extracellular stimulus signalling to the nucleus. However, BRAF is also the most often mutated kinase in human cancers resulting in hyperactivation of signalling. BRAF inhibitors are thus a target for cancer therapy treatments. Braftide is a decamer of BRAF sequence found in the dimer interface. It binds allosterically to BRAF preventing kinase activity of mono/dimeric forms. It also leads to the degradation of BRAF and downregulation of MAPK signalling. This creates an ideal dual function inhibitor of a key kinase in cancers such as metastatic melanoma.